Stockscreener 앱 받기
1.11
29.75%
0.2545
시장 영업 전:
1.14
0.03
+2.70%
Allakos Inc 주식(ALLK)의 최신 뉴스
Allakos Inc. (NASDAQ:ALLK) Shares Sold by Barclays PLC - Defense World
Jane Street Group LLC Has $34,000 Stake in Allakos Inc. (NASDAQ:ALLK) - Defense World
Atopic Dermatitis Clinical and Non-Clinical Studies, Key - openPR
BIOTECH MARKET RESEARCH $ALLK | Ep. 550 - substack.com
Geode Capital Management LLC Purchases 80,763 Shares of Allakos Inc. (NASDAQ:ALLK) - Defense World
Institutional owners may take dramatic actions as Allakos Inc.'s (NASDAQ:ALLK) recent 11% drop adds to one-year losses - Simply Wall St
Eosinophilic Gastroenteritis Treatment Market 2032: EMA, - openPR
Barclays PLC Lowers Stock Position in Allakos Inc. (NASDAQ:ALLK) - Defense World
Allakos Inc. (NASDAQ:ALLK) Short Interest Down 15.7% in December - Defense World
Allakos Inc. (NASDAQ:ALLK) Short Interest Update - MarketBeat
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm - Kilgore News Herald
BNP Paribas Financial Markets Sells 103,658 Shares of Allakos Inc. (NASDAQ:ALLK) - Defense World
Contrasting GT Biopharma (NASDAQ:GTBP) and Allakos (NASDAQ:ALLK) - Defense World
Fmr LLC Increases Stock Holdings in Allakos Inc. (NASDAQ:ALLK) - Defense World
Fmr LLC Buys 685,623 Shares of Allakos Inc. (NASDAQ:ALLK) - MarketBeat
Allakos's SWOT analysis: AK006 potential drives stock outlook amid challenges - Investing.com Australia
1,750,000 Shares in Allakos Inc. (NASDAQ:ALLK) Bought by Point72 Asset Management L.P. - MarketBeat
3 US Penny Stocks Under $200M Market Cap To Watch - Yahoo Finance
Alexandria Inks 259 KSF Bay Area Life Science Lease - Commercial Property Executive
Allakos Reports Q3 2024 Results and Research Progress - TipRanks
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy - MSN
Eosinophilic Esophagitis Market worth $1,767.2 Million by 2031, Coherent Market Insights - BioSpace
Allakos Inc. finalizes early lease termination, incurring $2.5 million in costs - Investing.com Canada
Allakos Inc. Alters Lease Agreement for Cost Savings - TipRanks
FMR LLC's Strategic Acquisition of Allakos Inc Shares - GuruFocus.com
Allakos's SWOT analysis: biotech firm's stock faces hurdles in CSU market - Investing.com
FY2024 EPS Estimates for Allakos Raised by Leerink Partnrs - MarketBeat
Allakos Runs Up Into A Near-Term Catalyst (NASDAQ:ALLK) - Seeking Alpha
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
10 Health Care Stocks Whale Activity In Today's SessionAllakos (NASDAQ:ALLK), Amgen (NASDAQ:AMGN) - Benzinga
Allakos perks up after early-stage data for lead asset - MSN
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire
Allakos Inc. (NASDAQ:ALLK) Short Interest Down 17.1% in October - MarketBeat
3 US Penny Stocks With Market Caps Larger Than $50M - Simply Wall St
Allakos Insiders Miss 24% Gain After Offloading Stock - Simply Wall St
Vernal Keratoconjunctivitis Market Growth to Accelerate - openPR
The Manufacturers Life Insurance Company Sells 2,148 Shares of Innoviva, Inc. (NASDAQ:INVA) - Defense World
Short Interest in Custom Truck One Source, Inc. (NYSE:CTOS) Decreases By 5.5% - Defense World
Nasal Polyposis Market Size is Set for Rapid Growth as Innovative - openPR
Chronic Spontaneous Urticaria Market Forecasted to Surge - openPR
Jefferies downgrades Allakos Inc (ALLK) stock to a Hold - Knox Daily
Allakos Inc (ALLK)’s stock price range in the last year - US Post News
Investor’s Delight: Allakos Inc (ALLK) Closes Weak at 0.65, Down -1.14 - The Dwinnex
Allakos shares hold rating after trial update By Investing.com - Investing.com Australia
Piper Sandler maintains Overweight rating on Allakos shares By Investing.com - Investing.com Australia
4.81%
자본화:
|
볼륨(24시간):